New Additions to Drugs.com for 2019
We update the Drugs.com database on a regular cycle. The following new drug information was added in 2019:
Nov 29, 2019 - Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD).
Nov 27, 2019 - Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients.
Nov 20, 2019 - Adakveo (crizanlizumab-tmca) is a P-selectin inhibitor for the prevention of vasoocclusive crises (VOCs) in patients with sickle cell disease (SCD).
Nov 18, 2019 - Brukinsa (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor indicated for the treatment of patients with mantle cell lymphoma (MCL).
Oct 30, 2019 - Vumerity (diroximel fumarate) is an oral fumarate for the treatment of relapsing forms of multiple sclerosis (MS).
Oct 23, 2019 - Trikafta (elexacaftor, ivacaftor and tezacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Oct 11, 2019 - Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
Oct 8, 2019 - Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.
Sep 20, 2019 - Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus.
Sep 13, 2019 - Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
Sep 9, 2019 - Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.
Sep 1, 2019 - Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “OFF” episodes.
Sep 1, 2019 - Rozlytrek (entrectinib) is a selective tyrosine kinase inhibitor for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer and neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors.
Aug 22, 2019 - Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Aug 19, 2019 - Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.
Aug 5, 2019 - Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Jul 24, 2019 - Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.
Jul 9, 2019 - Xpovio (selinexor) is a nuclear export inhibitor for the treatment of patients adult patients with relapsed or refractory multiple myeloma.
Jul 8, 2019 - Vyleesi (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Jun 11, 2019 - Slynd (drospirenone) is a progestin oral contraceptive for birth control.
May 30, 2019 - Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.
May 20, 2019 - Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.
May 7, 2019 - Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Apr 29, 2019 - Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.
Apr 28, 2019 - Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.
Apr 27, 2019 - Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis.
Apr 16, 2019 - Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Apr 15, 2019 - Dovato (dolutegravir and lamivudine) is a once-daily, single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and lamivudine (Epivir) indicated for the treatment of HIV-1 infection in adults.
Apr 15, 2019 - Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.
Apr 14, 2019 - Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Apr 1, 2019 - Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis.
Mar 28, 2019 - Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Mar 28, 2019 - Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).
Mar 6, 2019 - Spravato (esketamine) is a prescription nasal spray indicated for use in adults with treatment-resistant depression, and major depressive disorder (MDD) with acute suicidal ideation or behavior.
Feb 13, 2019 - Jeuveau (prabotulinumtoxinA) is a botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines.